{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alpelisib+300+mg", "query": { "intervention": "Alpelisib 300 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alpelisib+300+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T13:44:00.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05230810", "title": "Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Metastatic Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-08-25", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 4, "location_summary": "Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05230810" }, { "nct_id": "NCT05143229", "title": "Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Sacituzumab govitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-03-28", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 7, "location_summary": "Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05143229" }, { "nct_id": "NCT02273219", "title": "Trial of AEB071 in Combination With BYL719 in Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "AEB071", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2014-11-19", "completion_date": "2018-07-02", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 3, "location_summary": "Miami, Florida • New York, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273219" }, { "nct_id": "NCT07778524", "title": "Alpelisib Challenge Test (ACT)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Type 2 Diabetes", "Obesity & Overweight", "Healthy Adult Participants" ], "interventions": [ { "name": "Alpelisib 300 mg", "type": "DRUG" }, { "name": "Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib", "type": "DIAGNOSTIC_TEST" }, { "name": "Hyperglycemic clamp", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2026-09-01", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07778524" }, { "nct_id": "NCT05733455", "title": "Effect of Alpelisib in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Insulin Resistance", "Hyperinsulinemia", "Dyslipidemias" ], "interventions": [ { "name": "Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)", "type": "DRUG" }, { "name": "Placebo (microcrystalline cellulose), 2 capsules", "type": "DRUG" }, { "name": "FreeStyle Libre Pro", "type": "DEVICE" }, { "name": "Oral glucose tolerance test (OGTT) with Trutol glucose beverage", "type": "DIAGNOSTIC_TEST" }, { "name": "BOOST Plus nutritional beverage", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DEVICE", "DIAGNOSTIC_TEST", "DIETARY_SUPPLEMENT" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2023-05-09", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733455" }, { "nct_id": "NCT05501886", "title": "Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Alpelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2022-12-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05501886" }, { "nct_id": "NCT05090358", "title": "Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Stage IV", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ketogenic Diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Low Carbohydrate Diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Alpelisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-10-08", "completion_date": "2027-10-08", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 9, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "East White Plains", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090358" }, { "nct_id": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 383, "start_date": "2017-08-29", "completion_date": "2024-11-12", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 25, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056755" }, { "nct_id": "NCT04251533", "title": "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "alpelisib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 137, "start_date": "2020-06-08", "completion_date": "2026-02-05", "has_results": true, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 5, "location_summary": "Los Angeles, California • Baton Rouge, Louisiana • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04251533" }, { "nct_id": "NCT02077933", "title": "Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Breast Neoplasms", "Kidney Neoplasms", "Pancreatic Neuroendocine Neoplasms (pNETs)" ], "interventions": [ { "name": "alpelisib", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2014-05-14", "completion_date": "2019-04-12", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-09-01T13:44:00.214Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • New York, New York", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02077933" } ] }